Research Horizons


Roots of New Drug for HES Trace Back to Cincinnati Children’s

In 2008, Marc Rothenberg, MD, PhD, Director of the Division of Allergy and Immunology and the Cincinnati Center for Eosinophilic Disorders at Cincinnati Children’s, led an international group of investigators to conduct a randomized clinical trial that proved the ability of mepolizumab to lower oral steroid doses in patients with HES.

Read more about the FDA’s approval of mepolizumab